<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03893461</url>
  </required_header>
  <id_info>
    <org_study_id>S-20180109</org_study_id>
    <nct_id>NCT03893461</nct_id>
  </id_info>
  <brief_title>Coagulation System In STereotactic Radiotherapy Of NSCLC</brief_title>
  <acronym>CISTRON</acronym>
  <official_title>Impact of Stereotactic Body Radiation Therapy on the Coagulation System in Patients With Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The risk of thromboembolism is elevated in lung cancer patients. The present project&#xD;
      investigates whether stereotactic body radiation therapy (SBRT) further increases the risk of&#xD;
      thromboembolic disease in lung cancer patients.&#xD;
&#xD;
      If coagulation is activated by SBRT, this study could form the basis of new clinical trials&#xD;
      investigating whether lung cancer patients may benefit from thromboprophylaxis during and&#xD;
      after stereotactic body radiation therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, the patients will have blood samples drawn three times (prior to start of&#xD;
      stereotactic body radiation therapy, immediately after stereotactic body radiation therapy&#xD;
      completion, four to six weeks after completing stereotactic body radiation therapy). The&#xD;
      blood sample at the completion of stereotactic body radiation therapy is an extra compared to&#xD;
      normal gathering of blood samples of patients with NSCLC treated with stereotactic body&#xD;
      radiation therapy. Also extra glasses with blood will be gathered at each blood sample for&#xD;
      storage in a biobank in order to be able to make future analysis on this material.&#xD;
&#xD;
      There is a minimal risk of developing infection or hematoma in connection with blood sampling&#xD;
      but we consider this risk to be negligible. The total volume of 120 ml blood drawn over a&#xD;
      period of 6 weeks is an inconsiderable risk for the patient.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 26, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Actual">June 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in coagulation</measure>
    <time_frame>From start of SBRT to end and 5 weeks after SBRT</time_frame>
    <description>endogenous thrombin</description>
  </primary_outcome>
  <enrollment type="Actual">110</enrollment>
  <condition>Thromboembolism</condition>
  <condition>Lung Cancer</condition>
  <condition>NSCLC</condition>
  <condition>Radiotherapy; Complications</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>x</intervention_name>
    <description>Stereotactic body radiation therapy for localized NSCLC</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample collection for biobank&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        A prospective study of 100 consecutively included lung cancer patients receiving&#xD;
        stereotactic body radiation therapy. As standard treatment, which is considered for best&#xD;
        practice, the patients receive:&#xD;
&#xD;
          1. 66 Gy/ 3 fractions (F) (new primary peripheral lung cancer), or&#xD;
&#xD;
          2. 50 Gy/ 5 F (new primary central lung cancer), or&#xD;
&#xD;
          3. 45 Gy/ 3 F (peripheral lung cancer relapse after initial surgery or stereotactic body&#xD;
             radiation therapy)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Planned stereotactic body radiation therapy of lung cancer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to provide informed consent&#xD;
&#xD;
          -  Venous thrombosis within the last three months&#xD;
&#xD;
          -  Active cancer within the previous year except for lung cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan S Jeppesen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Oncology, Odense University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Oncology, Odense University Hospital</name>
      <address>
        <city>Odense C</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 26, 2019</study_first_submitted>
  <study_first_submitted_qc>March 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 28, 2019</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Stefan Starup Jeppesen</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

